SPRO vs. NTLA
SPRO (Spero Therapeutics, Inc.) and NTLA (Intellia Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, SPRO returned -27.74%/yr vs -29.01%/yr for NTLA. At a 0.31 correlation, their price movements are largely independent.
Performance
SPRO vs. NTLA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SPRO achieves a 20.17% return, which is significantly lower than NTLA's 44.83% return.
SPRO
- 1D
- -1.06%
- 1M
- 12.00%
- YTD
- 20.17%
- 6M
- 22.81%
- 1Y
- 6.06%
- 3Y*
- 15.44%
- 5Y*
- -27.74%
- 10Y*
- —
NTLA
- 1D
- -0.84%
- 1M
- -6.13%
- YTD
- 44.83%
- 6M
- 43.71%
- 1Y
- 69.31%
- 3Y*
- -31.75%
- 5Y*
- -29.01%
- 10Y*
- -7.63%
SPRO vs. NTLA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SPRO Spero Therapeutics, Inc. | 20.17% | 126.21% | -29.93% | -15.03% | -89.19% | -17.43% | 101.66% | 56.34% | -47.66% | 2.17% |
NTLA Intellia Therapeutics, Inc. | 44.83% | -22.90% | -61.76% | -12.61% | -70.49% | 117.35% | 270.82% | 7.47% | -28.98% | -8.48% |
Correlation
The correlation between SPRO and NTLA is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Nov 3, 2017 | 0.31 |
Fundamentals
SPRO:
$160.39M
NTLA:
$1.54B
SPRO:
$0.39
NTLA:
-$3.58
SPRO:
2.93
NTLA:
21.71
SPRO:
3.03
NTLA:
2.48
SPRO:
$54.77M
NTLA:
$66.09M
SPRO:
$54.51M
NTLA:
-$33.92M
SPRO:
$12.49M
NTLA:
-$299.32M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SPRO vs. NTLA — Risk / Return Rank
SPRO
NTLA
SPRO vs. NTLA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SPRO | NTLA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.61 | ||
| Sortino ratioReturn per unit of downside risk | -0.97 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.22 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 0.15 | 0.98 | -0.82 |
| Martin ratioReturn relative to average drawdown | 0.27 | 1.55 | -1.28 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SPRO | NTLA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.12 | 0.73 | -0.61 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.18 | -0.36 | +0.18 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.10 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.12 | -0.07 | -0.06 |
Drawdowns
SPRO vs. NTLA - Drawdown Comparison
The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for SPRO and NTLA.
Loading charts...
Drawdown Indicators
| SPRO | NTLA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.46% | -96.45% | -1.01% |
Max Drawdown (1Y)Largest decline over 1 year | -39.80% | -71.27% | +31.47% |
Max Drawdown (3Y)Largest decline over 3 years | -68.89% | -86.36% | +17.47% |
Max Drawdown (5Y)Largest decline over 5 years | -97.13% | -96.45% | -0.68% |
Max Drawdown (10Y)Largest decline over 10 years | — | -96.45% | — |
Current DrawdownCurrent decline from peak | -87.31% | -92.63% | +5.32% |
Average DrawdownAverage peak-to-trough decline | -62.29% | -57.04% | -5.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.79% | 44.93% | -22.14% |
Volatility
SPRO vs. NTLA - Volatility Comparison
The current volatility for Spero Therapeutics, Inc. (SPRO) is 17.76%, while Intellia Therapeutics, Inc. (NTLA) has a volatility of 18.74%. This indicates that SPRO experiences smaller price fluctuations and is considered to be less risky than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SPRO | NTLA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.76% | 18.74% | -0.98% |
Volatility (6M)Calculated over the trailing 6-month period | 32.23% | 53.80% | -21.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.43% | 95.55% | -43.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 151.57% | 80.62% | +70.95% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 124.80% | 78.25% | +46.55% |
Dividends
SPRO vs. NTLA - Dividend Comparison
Neither SPRO nor NTLA has paid dividends to shareholders.
Financials
SPRO vs. NTLA - Financials Comparison
This section allows you to compare key financial metrics between Spero Therapeutics, Inc. and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SPRO and NTLA have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NTLA has higher volatility (18.74%) compared to SPRO (17.76%). In terms of maximum drawdown, SPRO dropped -97.46% vs NTLA's -96.45%.
NTLA currently has the higher Sharpe Ratio (0.73 vs 0.12), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SPRO and NTLA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer